Guangzhou AoyuTirzepatide
Ordered Tirzepatide from Guangzhou Aoyu? Mail in a sample (US only) and let us test it for free.
Test my supplyRepeated June identity failures dominate this rating: three tests reported 0% purity, 0 mg found, and -100% fill after earlier 99.9% purity results. The record is volatile, with one clean Jun 15 test between failures.
Corporate records put the peptide storefront on a platform-only GlobalSources profile while older Aoyu listings sell unrelated goods. The report maps the identity stack, manufacturer-claim conflicts, missing credential trail, and clean-but-limited promotion sweep.
Unlock original COAs
View and download original lab PDFs for Finnrick tests, including Guangzhou Aoyu rows.
Cancel anytime
About Guangzhou Aoyu test results from Finnrick
Guangzhou Aoyu is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 4 peptides and 16 tests, including ratings, observed price signals, recent test dates, and correction history where available.
Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.
The most visible Guangzhou Aoyu peptides in this dataset are MOTS-c (2 tests), Retatrutide (3 tests) and Tesamorelin (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.
Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 16 recent tests.
Ordered Tirzepatide from Guangzhou Aoyu? Mail in a sample (US only) and let us test it for free.
Test my supply